New technology may be applicable to other autoimmune diseases and allergies
Results of a new phase 2 clinical trial using technology developed at Northwestern Medicine show it is possible to induce immune tolerance to gluten in individuals with celiac disease. The findings may pave the way for treated celiac patients to eventually tolerate gluten in their diet.
After treatment with the technology, the patients were able to eat gluten with a substantial reduction in inflammation. The results also show a trend toward protecting patients’ small intestine from gluten exposure.
The findings will be presented as a late-breaking presentation Oct. 22 at the European Gastroenterology Week conference in Barcelona, Spain.
The technology is a biodegradable nanoparticle containing gluten that teaches the immune system the antigen (allergen) is safe. Thenanoparticle acts like a Trojan horse, hiding the allergen in a friendly shell, to convince the immune system not to attack it.
Beyond celiac disease, the finding sets the stage for the technology — a nanoparticle containing the antigen triggering the allergy or autoimmune disease — to treat a host of other diseases and allergies including multiple sclerosis, type 1 diabetes, peanut allergy, asthma and more.
The technology was developed in the lab of Stephen Miller, professor of microbiology and immunology at Northwestern University Feinberg School of Medicine, who has spent decades refining the technology.
“This is the first demonstration the technology works in patients,” said Miller, the Judy Gugenheim Research Professor of Microbiology and Immunology.“We have also shown that we can encapsulate myelin into the nanoparticle to induce tolerance to that substance in multiple sclerosis models, or put a protein from pancreatic beta cells to induce tolerance to insulin in type 1 diabetes models.”
When the allergen-loaded nanoparticle is injected into the bloodstream, the immune system isn’t concerned with it, because it sees the particle as innocuous debris. Then the nanoparticle and its hidden cargo are consumed by a macrophage, essentially a vacuum-cleaner cell that clears cellular debris and pathogens from the body.
“The vacuum-cleaner cell presents the allergen or antigen to the immune system in a way that says, ‘No worries, this belongs here,’” Miller said. “The immune system then shuts down its attack on the allergen, and the immune system is reset to normal.”
In the celiac disease trial, the nanoparticle was loaded with gliadin, the major component of dietary gluten, found in cereal grains such as wheat. A week after treatment, the patients were fed gluten for 14 days. Without treatment, celiac patients eating gluten developed marked immune responses to gliadin and damage in their small intestine. Celiac patients treated with the COUR nanoparticle, CNP-101, showed 90% less immune inflammation response than untreated patients. By stopping the inflammatory response, CNP-101 showed the capacity to protect the intestines from gluten related injury.
There currently is no treatment for celiac disease.
“Doctors can only prescribe gluten avoidance, which is not always effective and carries a heavy social and economic toll for celiac patients,” Miller said.
About 1% of the population has celiac disease,a serious autoimmune disease in which the ingestion of gluten leads to damage in the small intestine. When people with celiac disease eat gluten (a protein found in wheat), their body mounts an immune response that attacks the small intestine.
Autoimmune diseases generally can only be treated with immune suppressants that provide some relief, but undermine the immune system and lead to toxic side-effects. CNP-101 does not suppress the immune system but reverses the course of disease.
“Celiac disease is unlike many other autoimmune disorders because the offending antigen (environmental trigger) is well known — gluten in the diet,” said Dr. Ciaran Kelly, professor of medicine at Harvard Medical School and director of the Celiac Center at Beth Israel Deaconess Medical Center. “This makes celiac disease a perfect condition to address using this exciting nanoparticle induced immune tolerance approach.”
Kelly, who will be presenting the research abstract in Barcelona, has been working with Miller to apply the technology and define the therapeutic approach to treating celiac disease.
The nanotechnology was licensed to COUR Pharmaceuticals Co., a biotech based in Northbrook and co-founded by Miller. COUR developed CNP-101, which was granted Fast Track status from the U.S. Food and Drug Administration, and brought the therapy to patients in collaboration with Takeda Pharmaceuticals. Takeda will announce Tuesday they have acquired an exclusive global license to develop and commercialize this investigational medicine for celiac disease.
“Given the license by Takeda, COUR will focus on clinical programs in peanut allergy and multiple sclerosis in the near term and broaden even further over time,” said John J. Puisis, president and chief executive officer of COUR.
Learn more: New treatment may reverse celiac disease
The Latest on: Celiac disease
[google_news title=”” keyword=”celiac disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Celiac disease
- Nemysis Ltd and Faran S.A. Sign a Strategic Agreement to Cooperate for the Development of Endopeptidase E40 for Celiac Diseaseon December 2, 2022 at 1:00 am
DUBLIN, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nemysis Ltd today announces a Strategic Cooperation with Faran S.A., a leading Greek pharma company, for the development and later commercialization of its ...
- Celiac Disease Testing Market 2023 Share, Size, Sales, Growth Drivers, Opportunities, Industry Trends and Forecast to 2028on December 1, 2022 at 1:50 am
A quantitative analysis is combined with a fresh perspective on the target industry in the Celiac Disease Testing ...
- Celiac Disease Market Is In Huge Demand | Global Growth, Historic Analysis, Future Trends, Growth Opportunity and Forecast Till 2028on December 1, 2022 at 12:16 am
In the forecast period of 2023-2028, the Global “Celiac Disease Market” is expected to grow at a steady rate, according to the Celiac Disease Market report, which summarizes the key aspects of the ...
- Who Has The Best Gluten Free Menu on Long Island?on November 29, 2022 at 9:33 pm
Long Islanders voted Bliss Pastries as having the Best Gluten Free Menu on Long Island in the 2022 Bethpage Best of Long Island contest!
- Serological test signals viral triggers of diseases like diabetes and celiac diseaseon November 29, 2022 at 7:58 am
A new serological test can not only help humanity prepare for and respond to the next pandemic, but it also can be pivotal in the search for viral triggers of diseases like diabetes and celiac disease ...
- The Spectrum of Celiac Disease: Epidemiology, Clinical Aspects and Treatmenton November 26, 2022 at 4:00 pm
Celiac disease is a gluten-sensitive enteropathy that affects people of all ages worldwide. This disease has emerged as a major health-care problem, as advances in diagnostic and screening methods ...
- Gluten Sensitivityon November 24, 2022 at 4:00 pm
ATA or anti-tTG released from damaged intestine during active disease. The intestinal T-cell response to a-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by ...
- Is celiac disease hereditary?on November 23, 2022 at 4:00 pm
Celiac disease is a hereditary condition that runs in families. People with a first-degree relative with celiac disease have a greater chance of developing it. Share on Pinterest Design by MNT ...
- Celiac Symptoms Common Despite Dietary Adherenceon November 22, 2022 at 10:31 am
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Nearly half of patients with celiac disease experienced clinically relevant events even while highly adherent to a ...
- Have Celiac Disease? You May Need Screening for Other Disorderson November 22, 2022 at 12:27 am
Nov. 18, 2022 -- Boston dietitian Katarina Mollo has virtually no memory of life without celiac disease. Diagnosed at age 4, Mollo has been on a gluten-free diet for 41 years that she says has ...
via Bing News